|
**Overview**: Parvovirus B19 Antibodies Panel**Introduction**: The Parvovirus B19 Antibodies Panel is a diagnostic tool designed to screen for parvovirus B19 using serum samples. In India, parvovirus B19 causes ~10-20 percent of aplastic crisis in hemolytic anemias (sickle cell, thalassemia), erythema infectiosum in children, and fetal hydrops in pregnant women (risk ~5-10 percent transmission). High morbidity from under-testing in rural/low-SES patients with transient red cell aplasia or pregnant women with rash/fever, limited serology labs, delayed supportive care or IVIG leading to severe anemia or fetal loss. Per microbiology practices aligned with ICMR and National Centre for Disease Control guidelines, the test employs immunoassay for parvovirus IgG and IgM over 1-2 days with high specificity, valuable for acute (IgM) or past (IgG) infection diagnosis. This diagnostic falls under infection screening and targets patients with aplastic crisis, rash, or pregnant women with exposure, addressing accurate detection to guide transfusion or IVIG. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise parvovirus assessment and reducing fetal/neonatal complications. Its serum-based approach ensures reliable antibody detection.**Other Names**: Parvo Ab Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: IgM/IgG serology standard; in India, used in hematology and obstetrics.**Purpose**: The test assesses 2 parameters including parvovirus IgG to guide infection screening, detect acute/past exposure, inform supportive therapy.**Test Parameters**: 1. Parvovirus IgG, 2. Parvovirus IgM.**Pretest Condition**: No fasting required; patients should have anemia or rash.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on rash, anemia, pregnancy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected parvovirus including fetal loss, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or early sampling can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgM indicates acute infection; IgG positive past exposure/immunity, necessitating specialist input.**Specialist Consultation**: Hematologists or obstetricians should be consulted for management.**Additional Supporting Tests**: PCR, fetal ultrasound for confirmation.**Test Limitations**: IgM may persist; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, Viral Studies India 2023. |
